Biogen has received an NOC from Health Canada for Zurzuvae, a NAS, as a treatment for moderate or severe PPD in women.

This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.

The bipolar disorder (BD) market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and ...

Roche has received EC approval for its humanised monoclonal antibody Gazyva, in combination with mycophenolate mofetil (MMF).

As Datwyler unveils its next-generation flip cap made with bio-based polypropylene, we spoke with Camille Ermine about the challenges and opportunities of eco-design in parenteral packaging, from ...

Relapsed or refractory (R/R) follicular lymphoma (FL) remains a therapeutic challenge despite recent advances. Credit: evan_huang via Shutterstock. Bristol Myers Squibb’s golcadomide, a first-in-class ...

Takeda and Innovent have closed their global partnership for next-generation IO and ADC therapies after fulfilment of ...

If approved, Regeneron and Tessera's TSRA-196 could become the first curative therapy to reach patients with AATD, who have ...

Agilent Technologies has expanded its collaboration with Monash University Malaysia (MUM) for the establishment of a ...

Høeg’s appointment to director of the FDA's CDER follows a turbulent period for the department, which has seen five leaders ...

Viatris has signed definitive agreements for the sale of its equity stake in Biocon Biologics to Biocon for $815m.

The UK becomes the latest country in President Donald Trump’s long line of trade agreements, though it is the first region to ...